A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
Jordi Rello, Claus-Georg Krenn, Gottfried Locker, Ernst Pilger, Christian Madl, Laura Balica, Thierry Dugernier, Pierre-Francois Laterre, Herbert Spapen, Pieter Depuydt, Jean-Louis Vincent, Lajos Bogár, Zsuzsanna Szabó, Barbara Völgyes, Rafael Máñez, Nahit Cakar, Atilla Ramazanoglu, Arzu Topeli, Maria A Mastruzzo, Abel Jasovich, Christian G Remolif, Liliana Del Carmen Soria, Max A Andresen Hernandez, Carolina Ruiz Balart, Ildikó Krémer, Zsolt Molnár, Frank von Sonnenburg, Arthur Lyons, Michael Joannidis, Heinz Burgmann, Tobias Welte, Anton Klingler, Romana Hochreiter, Kerstin Westritschnig, Jordi Rello, Claus-Georg Krenn, Gottfried Locker, Ernst Pilger, Christian Madl, Laura Balica, Thierry Dugernier, Pierre-Francois Laterre, Herbert Spapen, Pieter Depuydt, Jean-Louis Vincent, Lajos Bogár, Zsuzsanna Szabó, Barbara Völgyes, Rafael Máñez, Nahit Cakar, Atilla Ramazanoglu, Arzu Topeli, Maria A Mastruzzo, Abel Jasovich, Christian G Remolif, Liliana Del Carmen Soria, Max A Andresen Hernandez, Carolina Ruiz Balart, Ildikó Krémer, Zsolt Molnár, Frank von Sonnenburg, Arthur Lyons, Michael Joannidis, Heinz Burgmann, Tobias Welte, Anton Klingler, Romana Hochreiter, Kerstin Westritschnig
Abstract
Background: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy volunteers, patients with burns, and patients with chronic lung diseases. In order to assess the immunogenicity and safety of IC43 in patients who are most at risk of acquiring Pseudomonas infections, it was evaluated in mechanically ventilated ICU patients.
Methods: We conducted a randomized, placebo-controlled, partially blinded study in mechanically ventilated ICU patients. The immunogenicity of IC43 at day 14 was determined as the primary endpoint, and safety, efficacy against P. aeruginosa infections, and all-cause mortality were evaluated as secondary endpoints. Vaccinations (100 μg or 200 μg IC43 with adjuvant, or 100 μg IC43 without adjuvant, or placebo) were given twice in a 7-day interval and patients were followed up for 90 days.
Results: Higher OprF/I IgG antibody titers were seen at day 14 for all IC43 groups versus placebo (P < 0.0001). Seroconversion (≥4-fold increase in OprF/I IgG titer from days 0 to 14) was highest with 100 μg IC43 without adjuvant (80.6%). There were no significant differences in P. aeruginosa infection rates, with a low rate of invasive infections (pneumonia or bacteremia) in the IC43 groups (11.2-14.0%). Serious adverse events (SAEs) considered possibly related to therapy were reported by 2 patients (1.9%) in the group of 100 µg IC43 with adjuvant. Both SAEs resolved and no deaths were related to study treatment. Local tolerability symptoms were mild and rare (<5% of patients), a low rate of treatment-related treatment-emergent adverse events (3.1-10.6%) was observed in the IC43 groups.
Conclusion: This phase II study has shown that IC43 vaccination of ventilated ICU patients produced a significant immunogenic effect. P. aeruginosa infection rates did not differ significantly between groups. In the absence of any difference in immune response following administration of 100 μg IC43 without adjuvant compared with 200 μg IC43 with adjuvant, the 100 μg dose without adjuvant was considered for further testing of its possible benefit of improved outcomes. There were no safety or mortality concerns.
Trial registration: ClinicalTrials.gov, NCT00876252 . Registered on 3 April 2009.
Keywords: Bacterial infections; Immunity; Immunocompromised host; Mortality; Pseudomonas aeruginosa; Vaccination.
Figures
References
- National Nosocomial Infections Surveillance System National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85. doi: 10.1016/j.ajic.2004.10.001.
- Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, Leblebicioglu H, Khader IA, Novales MGM, Berba R, Wong FMR, Barkat A, Pino OR, Dueñas L, Mitrev Z, Bijie H, Gurskis V, Kanj SS, Mapp T, Hidalgo RF, Jaballah NB, Raka L, Gikas A, Ahmed A, Thu LTA, Siritt MEG, INICC members International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003–2008, issued June 2009. Am J Infect Control. 2010;38:95–106. doi: 10.1016/j.ajic.2009.12.004.
- Apostolopoulou E, Bakakos P, Katostaras T, Gregorakos L. Incidence and risk factors for ventilator-associated pneumonia in 4 multidisciplinary intensive care units in Athens. Greece Respir Care. 2003;48(7):681–8.
- Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903. doi: 10.1164/ajrccm.165.7.2105078.
- Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II group of investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323. doi: 10.1001/jama.2009.1754.
- Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582–610. doi: 10.1128/CMR.00040-09.
- Döring G, Pier GB. Vaccines and immunotherapy against P. aeruginosa. Vaccine. 2008;26(8):1011–24. doi: 10.1016/j.vaccine.2007.12.007.
- Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2012;186(5):420–7. doi: 10.1164/rccm.201202-0182OC.
- Mutharia LM, Hancock RE. Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies. Infect Immun. 1983;42(3):1027–33.
- Mansouri E, Gabelsberger J, Knapp B, Hundt E, Lenz U, Hungerer KD, Gilleland HE, Jr, Staczek J, Domdey H, von Specht BU. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun. 1999;67(3):1461–70.
- Larbig M, Mansouri E, Freihorst J, Tümmler B, Köhler G, Domdey H, Knapp B, Hungerer KD, Hundt E, Gabelsberger J, von Specht BU. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine. 2001;19:2291–7. doi: 10.1016/S0264-410X(00)00550-8.
- Göcke K, Baumann U, Hagemann H, Gabelsberger J, Hahn H, Freihorst J, von Specht BU. Mucosal vaccination with a recombinant OprF–I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol. 2003;37(2–3):167–71. doi: 10.1016/S0928-8244(03)00094-4.
- Mansouri E, Blome-Eberwein S, Gabelsberger J, Germann G, von Specht BU. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol Med Microbiol. 2003;37:161–6. doi: 10.1016/S0928-8244(03)00072-5.
- Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine. 2004;22(7):840–7. doi: 10.1016/j.vaccine.2003.11.029.
- Sorichter S, Baumann U, Baumgart A, Walterspacher S, von Specht BU. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine. 2009;27(21):2755–9. doi: 10.1016/j.vaccine.2009.03.010.
- Food and Drug Administration. Guidance for Industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. . Accessed 24 Jan 2017.
- Altman D, Machin D, Bryant T, Gardner M. Statistics with confidence. 2. Bristol: BMJ Books; 2000.
- Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. A randomized, placebo-controlled phase 1 study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother. 2013;10(1):170–83. doi: 10.4161/hv.26565.
- Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two phase 1 studies. Vaccine. 2012;30(9):1729–36. doi: 10.1016/j.vaccine.2011.12.045.
- Fito-Boncompte L, Chapalain A, Bouffartigues E, Chaker H, Lesouhaitier O, Gicquel G, Bazire A, Madi A, Connil N, Véron W, Taupin L, Toussaint B, Cornelis P, Wei Q, Shioya K, Déziel E, Feuilloley MGJ, Orange N, Dufour A, Chevalier S. Full virulence of Pseudomonas aeruginosa requires OprF. Infect Immun. 2011;79(3):1176–86. doi: 10.1128/IAI.00850-10.
- Wu L, Estrada O, Zaborina O, Bains M, Shen L, Kohler JE, Patel N, Musch MW, Chang EB, Fu YX, Jacobs MA, Nishimura MI, Hancock REW, Turner JR, Alverdy JC. Recognition of host immune activation by Pseudomonas aeruginosa. Science. 2005;309(5735):774–7. doi: 10.1126/science.1112422.
- Ding B, von Specht BU, Li Y. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa. Vaccine. 2010;28(25):4119–22. doi: 10.1016/j.vaccine.2010.04.028.
- Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754–8. doi: 10.1001/jama.286.14.1754.
- Grimwood K, Kyd JM, Owen SJ, Massa HM, Cripps AW. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother. 2015;11(1):14–20. doi: 10.4161/hv.34296.
- Committee for Medicinal Products for Human Use (CHMP). Guidance on clinical evaluation of new vaccines. 2006. . Accessed 24 Jan 2017.
Source: PubMed